BPI and Sepsis: Our findings are also consistent with a recent study showing that the administration of engineered MSCs expressing a fusion protein composed of a 21 kDa bioactive fragment of the bactericidal/permeability-increasing protein (BPI21) and LL-37 significantly reduced the inflammatory response, mitigated organ damage, and improved survival in mice with S. aureus-induced sepsis [43].